Psilocybin — Classic psychedelic / serotonin 5-HT2A agonist

The key pharmacological insight is that psilocybin's effects require a "therapeutic container" — set (mindset), setting (environment), and psychological support. As a standalone pharmacology discussion, raw 5-HT2A agonism cannot explain outcomes; the phenomenological experience and therapist integration sessions are integral to efficacy. SSRIs (especially long-term) blunt psilocybin effects via 5-HT2A receptor downregulation — patients may need a 2-week SSRI taper for full effect.

نظرة عامة

هذه الصفحة جزء من مكتبة المركّبات المُصنَّفة بالأدلة في Hormonaly. جميع الادعاءات السريرية مرتبطة بمصادر علمية مُحكَّمة عبر خط أنابيب التحقق المزدوج للاستشهادات.

فئة المركّب

Classic psychedelic / serotonin 5-HT2A agonist

آلية العمل

Full agonist at 5-HT2A serotonin receptors in prefrontal cortex; rapidly dephosphorylated to psilocin (active form). Produces neuroplasticity via BDNF/TrkB upregulation, default mode network (DMN) suppression, and increased global neural connectivity ("entropic brain" model). FDA Breakthrough Therapy for treatment-resistant depression (2018) and MDD (2019). Phase 2 data (COMPASS Pathways): 25mg psilocybin produced 29% remission rate vs 8% placebo at 3 weeks in TRD. Phase 3 ongoing. NOT FDA-approved.

الوضع التنظيمي

Investigational — Phase 3 ongoing; Oregon and Colorado legalized for supervised use

مستوى الأدلة

Moderate — Phase 2 RCTs; FDA Breakthrough designation; NOT yet Phase 3 complete